Earlier this month, members of the Parkinson’s Foundation team joined thousands of movement disorder specialists in Vancouver. They were on site for the International Congress of Parkinson’s Disease and Movement Disorders, which brings together neurologists with expertise in Parkinson’s and similar diseases to share advances in research and care. During the congress, our team shared four posters highlighting Parkinson’s Foundation innovations.
This week, members of our team are in Florida for an exciting first-time medical meeting, the Pan American Parkinson’s Disease and Movement Disorders Congress. It brings together a subset of a global group of professionals who research and treat movement disorders, including Parkinson’s. Scientists and health professionals are gathering at this meeting to share the latest research and to answer the question: how can we advance care for people with Parkinson’s and movement disorders in North America, Central America, South America and the Caribbean? Not only that, groundbreaking research funded by the Foundation is front-and-center.
A few months back, Dr. James Beck, PDF’s Director of Research Programs attended the annual Movement Disorder Society annual meeting. Among the many scientific sessions and meetings, was a gathering of the team behind LARGE- PD, the Latin American Research Consortium on the Genetics of Parkinson’s Disease. Just today that team sent us a photo of that meeting – where they discussed their investigations into Parkinson’s and genetics in Argentina, Brazil, Peru and Uruguay. They are led in these efforts by Cyrus Zabetian, M.D., M.S., of the University of Washington in Seattle, WA. Learn more about this study
On Tuesday, June 9th, the second day of the Movement Disorder Society International Congress in Paris, Dr. Warren Olanow, one of the world’s leading Parkinson’s specialists, gave a brilliant and authoritative talk on the subject of “What’s New in Parkinson’s Trials?” His focus was three high-profile clinical trials that have been watched intently and anxiously by people with Parkinson’s around the world. One was the Ceregene trial, in which a growth factor called neurturin (CERE-120) was delivered via a gene therapy technique. The second was STRIDE, in which a levodopa-COMT inhibitor (Stalevo(R)) was tested for its potential impact on improving… Read More